The Accessible Canada Directorate within Employment and Social Development Canada (ESDC) has engaged Quorus Consulting Group to conduct the second cycle of public opinion research measuring Canadians’ awareness and experience(s) […]

WILLS AND ESTATES Help Canadians Affected by Osteoporosis by Leaving a Gift in Your Will When you leave a gift to Osteoporosis Canada in your Will, you can feel confident […]

PROVINCIAL DRUG COVERAGE AS OF FEBRUARY 2024 Coverage is under constant review and is subject to change. Access to a generic equivalent is generally reported to be identical to that […]

Latest News Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis. May 31, 2024 Health Canada has provided authorization to market Jubbonti® (denosumab […]

Important Changes to the Availability and Conditions of Use for Drugs Containing Calcitonin Calcitonin nasal spray for the treatment of osteoporosis is no longer available in Canada because of new […]

Available Volunteer Opportunities Call for Nominations – Board of Directors After evaluating the strengths of the existing Board of Directors, the Board Development Committee is seeking individuals with the following […]

PARATHYROID HORMONE (PTH) A new class of osteoporosis treatments called bone formation agents Parathyroid hormone analogues belong to a class of osteoporosis medications which can promote bone growth. In Canada, […]

VITAMIN D IS VERY IMPORTANT TO OUR BONE HEALTH When taken in the appropriate amount, vitamin D decreases our risk of falling and breaking bones. It is very common to […]

Treatments Did you know? Osteoporosis leads to fragility fractures. These are broken bones that happen from a minor injury but that have major consequences such as pain, disability and sometimes […]